Previous 10 | Next 10 |
CohBar, Inc. (CWBR) Q2 2020 Earnings Conference Call August 13, 2020, 05:00 PM ET Company Participants Jordyn Tarazi - Director of IR Steve Engle - CEO Ken Cundy - Chief Scientific Officer Jeff Biunno - CFO Conference Call Participants Kumar Raja - Brookline Capital Marke...
CohBar (NASDAQ: CWBR ) : Q2 GAAP EPS of -$0.09 misses by $0.03 . More news on: CohBar, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
New positive preliminary preclinical results in ARDS model Company to host conference call and webcast at 5:00 p.m. ET MENLO PARK, Calif., Aug. 13, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics t...
4 Cheap Stocks To Watch This Week Penny stocks are definitely considered “affordable” but let’s not get than confused with “cheap”. When it comes to these small- and micro-cap companies, the price tag of the stock itself shouldn’t be the only thing y...
MENLO PARK, Calif., Aug. 05, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its ePoster featuring new antifibrotic data i...
MENLO PARK, Calif., July 30, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that the company will release its second quarter 2...
MENLO PARK, Calif., July 07, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced that it has resumed the Phase 1b stage of its Phase 1a/...
MENLO PARK, Calif., July 06, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief Executive Officer, Steven Engle, will pr...
MENLO PARK, Calif., June 30, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, was added to the US small-cap Russell 2000® Index during the 2020 ...
MENLO PARK, Calif., June 17, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced the publication of “AGE LATER: Health Span, Life...
News, Short Squeeze, Breakout and More Instantly...
3D Systems Corporation (DDD) is expected to report $-0.11 for Q1 2024 ZW Data Action Technologies Inc. (CNET) is expected to report for Q1 2024 Celularity Inc. (CELU) is expected to report for Q1 2023 DMK Pharmaceuticals Corporation (DMKPQ) is expected to report for Q1 2024 Atlant...
ADDvantage Technologies Group Inc. (AEYGQ) is expected to report for Q1 2024 ContraFect Corporation (CFRXQ) is expected to report for Q1 2024 American Clean Resources Group Inc (ACRG) is expected to report for Q1 2024 Atlantic Lithium Ltd Ord Fully Paid (ALLIF) is expected to report f...
Windtree Therapeutics Inc. (WINT) is expected to report for Q1 2024 CohBar Inc. (CWBR) is expected to report for Q1 2024 hopTo Inc (HPTO) is expected to report for Q1 2024 Bitech Technologies Corporation (BTTC) is expected to report for Q1 2024 Roadzen Inc. (RDZN) is expected to r...